News Takeda Pharmaceutical Company Limited Deutsche Boerse AG

Equities

TKDA

US8740602052

Real-time Estimate Tradegate Other stock markets 16:30:01 17/06/2024 BST			5-day change	1st Jan Change
12.25 ^EUR	+2.08%		-2.44%	-4.76%

03:35pm	Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback	DJ
03:21pm	Sector Update: Health Care Stocks Decline Premarket Monday	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback	02:35pm	DJ
Sector Update: Health Care Stocks Decline Premarket Monday	02:21pm	MT
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell	01:59pm	MT
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall	01:13pm	MT
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints	01:00pm	MT
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies	12:32pm	DJ
Takeda's seizure drug fails to meet main goal in late-stage studies	12:07pm	RE
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome	11:55am	CI
Takeda Pharmaceutical : Announces Phase 3 Topline Results for Soticlestat (TAK 935) in Patients with Dravet Syndrome and Lennox Gastaut Syndrome Form 6 K	11:50am	PU
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome	11:46am	BU
Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome	11:45am	CI
Takeda Signs Option Agreement with Ascentage to License Leukemia Drug	06-14	MT
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)	06-14	BU
Takeda Pharmaceutical Company Limited Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, Third-Generation BCR-ABL Tyrosine Kinase Inhibitor	06-14	CI
Takeda Issues New Shares, Disposes of Treasury Shares Under Long-term Incentive Plan for Employees	06-11	MT
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts	06-11	BU
Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long Term Incentive Plan for Company Group Employees Outside of Japan Form 6 K	06-11	PU
Takeda Pharmaceutical Prices Second Hybrid Bonds for 460 Billion Yen	06-10	MT
TAKEDA PHARMACEUTICAL : Form 6 K	06-10	PU
Takeda Pharmaceutical : Statement from Masami Iijima, Chair of the Board of Directors Meeting of Takeda, in Response to Institutional Shareholder Services Inc.’s Voting Recommendations Ahead of the 148th Ordinary General Meeting of Shareholders Form 6 K	06-07	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Takeda Pharmaceutical Company Limited Deutsche Boerse AG

Equities

TKDA

US8740602052

Summary

Filters